chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a 68 year old female with high cholesterol and allergy to Demerol and codeine and a history of bypass surgery who on 09-APR-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  Concomitant therapy included TOPROL XL TABLETS, ezetimibe (MSD) and CRESTOR.  It was reported that the patient had 5 breakouts of shingles since vaccination.  Unspecified medical attention was sought.  No diagnostic laboratory tests were undertaken.  At the time of report the patient had not recovered.  A product quality complaint was not involved.  Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: No adverse reaction, Wrong drug administered
Clinical narrative: Information has been received from a physician concerning a patient on 25-JUN-2007 was vaccinated with ZOSTAVAX. Subsequently the patient was given ZOSTAVAX (lot # 656395/0290U) rather than VARIVAX. No adverse symptoms were reported. Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Cough
Clinical narrative: Information has been received from a physician concerning a male who was vaccinated with ZOSTAVAX. Subsequently the patient experienced cough. This is one of two reports from the same source. Additional information has been requested.
Age: 80.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster, Rash vesicular
Clinical narrative: Information has been received from a pharmacist concerning an 80 year old female with hypertension and no allergies who on 08-JUN-2007 was vaccinated with a single dose of Zostavax (Oka/Merck).  Concomitant therapy included atenolol, hydrochlorothiazide and aspirin.  It was reported that on 26-JUN-2007 the patient developed herpes zoster like rash on her abdomen.  The patient had developed vesicles on her arm on 04-JUN-2007, prior to vaccination.  The details about the rash and it's location were unknown.  The patient was treated with VALTREX on 27-JUN-2007.  No diagnostic laboratory tests were undertaken.  At the time of report the patient had not recovered.  Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a nurse practitioner concerning a patient who was vaccinated with a 0.5 ml dose of ZOSTAVAX. It was reported that the patient developed shingles. Unspecified medical attention was sought. A product quality complaint was not involved. Additional information has been requested.
Age: 81.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a nurse concerning an 82 year old female who on 08-NOV-2006 was vaccinated in the right arm with Zostavax (Oka/Merck) (625925/0621F).  On 15-JUN-2007 the patient experienced shingles.  The patient recovered on 29-JUN-2007.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Rash vesicular, Varicella
Clinical narrative: Information has been received from a physician concerning a female who was vaccinated with a 0.65 ml dose of ZOSTAVAX. it was reported that the patient developed a chickenpox like rash. Unspecified medical attention was sought. A product quality complaint was not involved. Additional information has been requested.
Age: 61.0
Sex: F
Vaccine: VARZOS
Symptoms: Diarrhoea, Injection site erythema, Injection site pain, Pyrexia, Vomiting
Clinical narrative: Information has been received from a 61 year old female who on 12-JUN-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  Concomitant therapy included alendronate sodium (MSD), vitamin D (unspecified), BUSPAR and LEXAPRO.  On 12-JUN-2007 within a couple of hours the patient experienced pain and redness at injection site, within an hour or two after that she experienced vomiting, diarrhea and fever.  These symptoms lasted about 2 days, the patient recovered.  No medical attention was sought.  No product quality complaint.  No further information is available.
Age: 67.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster, Rash
Clinical narrative: information has been received from a physician concerning an approximately 67 year old male who was vaccinated with a 0.65 ml dose of ZOSTAVAX. It was reported that about 2 weeks after vaccination, the patient developed a rash as a two spots on the inner thigh. The physician suspected it as shingles but was not sure. Unspecified medical attention was sought. A product quality complaint was not involved. Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Accidental exposure, Blister
Clinical narrative: Information has been received from a pharmacist concerning a mid 30 years old female nurse who on 27-JUN-2007 was drawing up a dose of Zostavax (Oka/Merck) and a small amount of the vaccine splashed onto her left forearm above the level of her gloves.  The patient washed the affected area.  On 28-JUN-2007 the patient developed small blister like areas with a pinpoint white centers.  The blisters were at the area of the splash and did not spread any further.  It was reported that the patient had a topical exposure.  There were no complaints of itching or pain at the blister site.  Unspecified medical attention was undertaken.  At the time of report the patient was recovering.  A product quality complaint was not involved.  Additional information has been requested.
Age: 77.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster, Pruritus
Clinical narrative: Information has been received from a physician concerning a 77 year old male who on approximately 15-JUN-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  On approximately 16-JUN-2007, one day after vaccination the patient developed shingles.  It was reported that it was not at the injection site, but the patient had a T10 distribution of shingles.  The physician reported the case as mild, not painful and slightly itchy.  The patient was treated with 500 IPD of FAMVIR for 7 days.  A product quality complaint was not involved.  Additional information has been requested.
Age: 66.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site bruising
Clinical narrative: Information has been received from a pharmacist concerning a 66 year old female who on 21-JUN-2007 was vaccinated SC with a 0.65 ml dose of ZOSTAVAX. It was reported that the patient developed a bruise at an injection site. Unspecified medical attention was sought. No diagnostic laboratory tests were undertaken. At the time of report the patient had not recovered. A product quality complaint was not involved. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: No adverse reaction, Wrong drug administered
Clinical narrative: Information has been received from a physician concerning an unknown number of patients who were vaccinated with a dose of ZOSTAVAX. it was reported that the patients were supposed to receive a dose of VARIVAX. It was reported that the office had run out of VARIVAX and the nurse had been giving 1 year old children ZOSTAVAX instead. It was reported that ZOSTAVAX had been administered to children over approximately during the month of May 2007 and June 2007. The physician reported that she was not aware of any adverse events or Varicella in the patients. The physician stated that the office was in process of contacting the parent/gardian of every child who received ZOSTAVAX. The office had planned to develop a standard "questionnaire" that would be used to obtain consistent information. The physician also stated that she did not know exactly how many children were involved and stated that it could be a "large number". Attempts are being made to obtain additional identifying information to distinguish the individual patients mentions in this report. Additional information will be provided if available.
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site pruritus, Injection site rash
Clinical narrative: Information has been received from a pharmacist concerning a 65 year old female who on 27-JUN-2007 was vaccinated SC on left arm with a dose of Zostavax (Oka/Merck).  On 29-JUN-2007 the patient developed rash at the injection site.  The rash was described as red and itchy.  The patient was not evaluated by her physician and no treatment was ordered.  A medical attention was sought from the pharmacist.  A product quality complaint was not involved.  Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Rash vesicular
Clinical narrative: Information has been received from a pharmacist concerning a patient who was vaccinated with a dose of Zostavax (Oka/Merck).  It was reported that the patient developed shingles like rash after vaccination.  The pharmacist reported that the patient may have been immunocompromised.  A product quality complaint was not involved.  Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Syncope
Clinical narrative: Information has been received from a physician concerning a male who was vaccinated with a dose of Zostavax (Oka/Merck).  It was reported that the patient fainted shortly after vaccination.  Unspecified medical attention was sought.  At the time of report the patient had recovered.  A product quality complaint was not involved.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Injection site vesicles
Clinical narrative: Information has been received from a physician concerning a female who on an unspecified date "about a month ago," approximately June 2007, was vaccinated with a dose of Zostavax (Oka/Merck).  Subsequently the patient experienced mild blisters at injection site. Unspecified medical attention was sought.  On an unspecified date, the patient recovered.  No product quality complaint was involved.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Post herpetic neuralgia, Varicella
Clinical narrative: Information has been received from a female patient, a physician, who on 31-MAY-2007 was vaccinated with a "single dose" of Zostavax (Oka/Merck) (lot# 656609/0015U).  On 02-JUN-2007 the patient broke out in chicken pox.  The chicken pox resolved on 02-Jul-2007.  On an unspecified date, sometime after the chickenpox, it is reported that the patient experienced post herpetic neuralgia.  Unspecified medical attention was sought.  At the time of the report, the outcome of post herpetic neuralgia is reported as not recovered. No product quality complaint was involved.  Additional information has been requested.
Age: 69.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster, Rash
Clinical narrative: Information has been received from a 69-year-old male with an allergy to penicillin, prostate cancer that was treated with external beam radiation therapy in January and February of 2007 and seed implants on 15-Mar-2007, and has had "about 4 bouts with shingles over the last 2 or 3 years," who on 01-JUN-2007 was vaccinated with a 0.65 milliliter dose of Zostavax (Oka/Merck).  Concomitant therapy included ezetimibe (+) simvastatin (MSD), COREG and BENICAR.  The patient was on acyclovir therapy but discontinued about "48 hours before receiving the vaccine."  On approximately 29-JUN-2007, "about 28 days after vaccination," the patient developed shingles with "skin eruptions around eye and the base of the spine."  The patient did not "resume acyclovir therapy again until the shingles surfaced again".  Unspecified medical attention was sought.  The outcome is reported as recovering.  No product quality complaint was involved.  Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received concerning a patient who on an unspecified date was vaccinated with a dose of Zostavax (Oka/Merck).  Subsequently the patient developed shingles.  No other information was provided.  There was no product quality complaint involved.  Additional information has been requested.
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Arthropod bite, Blood pressure, Discomfort, Erythema, Excoriation
Clinical narrative: Initial information has been received from a physician assistant concerning a 65 year old retired female who on 06-FEB-2007, was vaccinated in the left deltoid with a 0.5 ml dose of Zostavax (Oka/Merck) (lot# "0011U").  On 26-JUL-2007 the patient developed a rash on the back of her arm.  She visited an urgent care center, was diagnosed with shingles and given VALTREX.  At the time of this report the patient's status was unspecified.  No additional information was provided.  There was no product quality complaint involved.  Follow up information has been received from the physician and physician assistant.  The patient has no known allergies.  There is a history of esophageal endoscopy (16-FEB-2006) which was normal, left ventriculography, coronary angiography, and left heart cut-down catheterization all on 06-FEB-2006 and a history of tobacco use.  There is also a history of chickenpox as a child.  There are current conditions of hypertension, diabetes mellitus (Type II), coronary artery disease, GERD, carpal tunnel syndrome, depression, and anxiety.  The patient was seen in the office on 27-JUL-2007 for her red rash which caused minimal discomfort and no burning or pain.  The onset of her rash was sudden and had been occurring in a persistent pattern for 2 days.  The course had been consistent.  The rash was first seen on her back.  The physician stated that this was not shingles.  The lesions on the right posterior shoulder were a small superficial wound which was a tick bite and two small abrasions below with mild erythema, there were no vesicular lesions.  Follow up information from the physician's assistant indicated that on 01-AUG-2007 the patient recovered.
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Heart rate normal, Incorrect dose administered, Rash erythematous, Respiratory rate
Clinical narrative: Initial information has been received from a physician assistant concerning a 65 year old retired female who on 06-FEB-2007, was vaccinated in the left deltoid with a 0.5 ml dose of Zostavax (Oka/Merck) (lot# "0011U").  On 26-JUL-2007 the patient developed a rash on the back of her arm.  She visited an urgent care center, was diagnosed with shingles and given VALTREX.  At the time of this report the patient's status was unspecified.  No additional information was provided.  There was no product quality complaint involved.  Follow up information has been received from the physician and physician assistant.  The patient has no known allergies.  There is a history of esophageal endoscopy (16-FEB-2006) which was normal, left ventriculography, coronary angiography, and left heart cut-down catheterization all on 06-FEB-2006 and a history of tobacco use.  There is also a history of chickenpox as a child.  There are current conditions of hypertension, diabetes mellitus (Type II), coronary artery disease, GERD, carpal tunnel syndrome, depression, and anxiety.  The patient was seen in the office on 27-JUL-2007 for her red rash which caused minimal discomfort and no burning or pain.  The onset of her rash was sudden and had been occurring in a persistent pattern for 2 days.  The course had been consistent.  The rash was first seen on her back.  The physician stated that this was not shingles.  The lesions on the right posterior shoulder were a small superficial wound which was a tick bite and two small abrasions below with mild erythema, there were no vesicular lesions.  Follow up information from the physician's assistant indicated that on 01-AUG-2007 the patient recovered.
Age: 72.0
Sex: M
Vaccine: VARZOS
Symptoms: Burning sensation, Pain in extremity
Clinical narrative: Information has been received from a 72 year old male with pain from shingles side effects over the past 15 years who on 19-APR-2007 was vaccinated with Zostavax (Oka/Merck). The patient saw the physician on 10-MAY-2007 and 11-JUN-2007 because his right foot and entire leg were still very painful with a burning sensation. He was prescribed 2 different pills, none of which have done any good. The patient's painful and burning right foot and entire leg persisted. Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Information has been received from a physician concerning a patient who was vaccinated with a first dose of 0.65 milliliters of Zostavax (Oka/Merck).  Subsequently, on an unspecified date the patient experienced a rash-like reaction.  Unspecified medical attention was sought.  The outcome is not reported.  No product quality complaint was involved.  This is one of several reports from the same source.  Additional information has been requested.
Age: 80.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Initial and follow up information has been received from a physician concerning an 80 year old female who in approximately JUNE 2007 was vaccinated subcutaneously with a single dose of Zostavax (Oka/Merck).  On 18-JUN-2007 the patient developed shingles on her left chest wall, left breast, and abdomen (previously reported as side).  Unspecified medical attention was sought.  Subsequently the patient recovered.  No further information was provided.  There was no product quality complaint involved.  No further information is expected.
Age: 81.0
Sex: M
Vaccine: VARZOS
Symptoms: Blister, Injection site discolouration, Rash vesicular
Clinical narrative: Information has been received from the wife of an 81-year-old male with no pertinent medical history and an allergy to "a certain antibiotic" who on 10-JUL-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  Concomitant therapy included NEXIUM, OMEGA-3, CADUET, Bayer, ARICEPT and hydrochlorothiazide (manufacturer unknown).  On approximately 12-JUL-2007 "a couple days" post vaccination, the patient experienced blisters sporadically from his neck to his ankles that looked like chicken pox.  He also developed a purple discoloration at the injection site.  Unspecified medical attention was sought.  No laboratory or diagnostic tests were performed.  The outcome is reported as recovering.  No product quality complaint was involved.  This is one of several reports from the same source.  Additional information has been requested.
Age: 75.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a consumer regarding her mother, who has no known allergies or pertinent medical history, who on 17-JUL-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  The patient was on no concomitant medication.  On 30-JUL-2007 the patient was diagnosed with shingles.  Unspecified medical attention was sought.  No lab studies were performed.  A the time of this report the patient had not recovered.  No other information was provided.  There was no product quality complaint involved.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Wrong drug administered
Clinical narrative: Information has been received from a registered nurse (R.N.) concerning a female who on 30-JUL-2007 was vaccinated intramuscularly with a 0.5 milliliter dose of Zostavax (Oka/Merck) (MSD) instead of Varivax.  It was unspecified if medical attention was sought.  The outcome is not reported.  No product quality complaint was involved.  Follow-up information received on 10-Aug-2007 indicates that all follow-up attempts have been unsuccessful.  No more information is expected.
Age: 61.0
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a physician concerning a 61 year old patient who on 25-JUL-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  On 27-JUL-2007 the patient developed shingles.  Medical attention was sought and VALTREX was prescribed for the symptoms.  No further information was provided.  There was no product quality complaint involved.  Additional information is not expected.
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site pain, Urticaria
Clinical narrative: Information has been received from an "about 60" year-old female with a history of breast cancer who on 14-JUN-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  "After receiving the vaccination, she experienced a sore arm around the injection site area."  After a week, on approximately 21-Jun-2007, she experienced rash-like symptoms and consulted a dermatologist who diagnosed her with a case of hives.  The patient was prescribed antihistamines and prednisone.  The outcome is reported as not resolved.  No product quality complaint was involved.  Additional information has been requested.
Age: 74.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site inflammation, Injection site swelling
Clinical narrative: This is in follow-up to report (s) previously submitted on 9/24/2007. Information has been received from a registered nurse (R.N.) concerning a female "over 60 years of age" who was vaccinated with a subcutaneous injection of Zostavax (Oka/Merck). Subsequently, on an unspecified date, the patient experienced "injection site swelling which was severely inflated and enormous." The patient visited the physicians office for follow-up where they treated her with steroids to keep inflammation down. The outcome is not reported. No product quality complaint was involved. Additional information received indicates that the patient is a 74-year-old female with allergies to sulfa, tape, and amoxicillin, and concurrent medical conditions IBS, GERD, mirgraines and hypothyroidism. On 16-Jul-2007 at 11:30, the patient received an intramusclar dose in the left deltoid of PNEUMOVAX 23 (LOT# 655592/0662F) (previously reported as zoster vaccine live (Oka/Merck)). Concomitant medications included FIORICET TABLETS, ALLERGRA, PREVACID, LEVOXYL, TIGAN, PROVIGIL, montelukast sodium (MSD), LORAZEPAN, "onlan" and "suspar". There was no illness at the time of vaccination. On 18-Jul-2007, the patient developed redness, welts and pain at the injectio site. The area below the injection site was moderately swollen. No laboratory or diagnostic test were performed. The patient was given 60 milligrams intramuscularly or KENALOG, and oral prednisone. On 23-Jul-2007, the patient recovered. The reporter considered the adverse events to be other important medical events that required medical attention. Additional information is not expected.
Sex: F
Vaccine: VARZOS
Symptoms: Rash vesicular
Clinical narrative: Information has been received from a physician concerning a female with a history of non-specific viral illnesses and chicken pox, who was vaccinated on an unspecified date subcutaneously with her first dose of Zostavax (Oka/Merck).  Subsequently, "one week post vaccination" the patient experienced "a VZV like rash located all over her body."  Unspecified medical attention was sought.  The outcome is reported as recovered.  No product quality complaint was involved.  Additional information has been requested.
Age: 76.0
Sex: F
Vaccine: VARZOS
Symptoms: Condition aggravated, Herpes zoster
Clinical narrative: Information has been received from a 76-year-old female with hypertension, hypothyroidism and no allergies, who in April 2007, was vaccinated with a subcutaneous "single 0.65 injection" of Zostavax (Oka/Merck).  Concomitant therapy included PLAVIX, simvastatin (MSD) and SYNTHROID.  On 27-JUL-2007 the patient developed shingles.  It is unknown if she had a previous history of herpes zoster.  Unspecified medical treatment was sought.  No diagnostic or laboratory test were ordered.  The outcome is reported as not recovered.  No product quality complaint was involved.  Additional information has been requested. 12/21/07 This is in follow-up to report(s) previously submitted on 9/24/2007. Follow-up information received from the consumer states "I got the worst case of shingles I ever had over the past 15 years, after I had the shot." Additional information has been requested.
Age: 63.0
Sex: F
Vaccine: VARZOS
Symptoms: Pruritus, Rash pruritic
Clinical narrative: Information has been received from a 63 year old female consumer with a history of hives who on 12-JUN-2007 was vaccinated with a dose of Zostavax (Oka/Merck). In approximately July 2007 "a month after receiving vaccine", the patient experienced itching in her right arm. The consumer reported that itching started 2 inches from wrist and is 3 inches from the injection site. The consumer sought unspecified medical attention. The consumer reported that she had been rubbing hydrocortisone to help relieve the itching. At the time of the report the patient had not recovered. There was no product quality complaint involved. Additional information has been requested. 12/21/2007 This is in follow-up to report(s) previously submitted on 9/24/2007. Information has been received from a 63 year old female with osteopenia, hyperglycemia, hyperlipidaemia, hypertension and a history of hives who on 12-JUN-2007 at 15:30 PM was vaccinated with a first dose of ZOSTAVAX (Oka/Merck) (Lot # 656395/0290U). There was no illness at the time of vaccination. In approximately July 2007 "a month after receiving vaccine", the patient experienced itching in her right arm. The consumer reported that itching started 2 inches from wrist and is 3 inches from the injection site. The consumer sought unspecified medical attention. The consumer reported that she had been rubbing hydrocortisone to help relieve the itching. At the time of the report the patient had not recovered. There was no product quality complaint involved. Additional information has been received from the physician who stated that the patient developed itchy rash on right arm starting at injection site. The patient applied CORTAID. The patient recovered after 6 to 8 weeks. No further information is expected.
Age: 70.0
Sex: F
Vaccine: VARZOS
Symptoms: Rash
Clinical narrative: Information has been received from the husband of a 70-year-old female with high blood pressure, allergies to tetracycline and ANTIVERT who was vaccinated "11 days ago", on approximately 19-Jul-2007, with a dose of Zostavax (Oka/Merck).  Concomitant therapy included acyclovir and VALTREX.  Subsequently "about 4 days ago", approximately 26-Jul-2007, the patient "broke out in a rash around her ribs that was about a 10 inch area."  Unspecified medical attention was sought.  No laboratory of diagnostic tests were performed.  The outcome is reported as not recovered.  No product quality complaint was involved.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Injection site induration, Injection site pruritus
Clinical narrative: Information has been received from a female consumer who was vaccinated on an unspecified date with a dose of Zostavax (Oka/Merck).  Subsequently the patient experienced a hard, itchy two inch square at the injection site.  It was unspecified if medical attention was sought.  No outcome was reported.  This is one of several reports by the same reporter.  Additional information has been requested.
Age: 76.0
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Pain, Pruritus, Swelling
Clinical narrative: Initial and follow up information has been received from a pharmacist concerning a 76 year old female patient who on 26-JUL-2007 at 11:00 was vaccinated SC in the right upper arm with a single first dose of Zostavax (Oka/Merck) (Lot#658081/0743U).  Subsequently the patient developed redness, itching, soreness, and swelling after the vaccination.  Unspecified medical attention was sought.  The pharmacist advised the patient to take BENADRYL 25 mg.  The patient did and after 24 hours the symptoms resolved.  No further information was provided.  There was no product quality complaint involved.  Additional information is not expected.
Age: 60.0
Sex: M
Vaccine: VARZOS
Symptoms: Incorrect route of drug administration, Influenza like illness
Clinical narrative: Initial and follow up information has been received from a physician concerning a 60 year old male journalist who on 14-MAR-2007 was vaccinated IM in the left deltoid, (previously reported as SC) with a single first dose of Zostavax (Oka/Merck) (Lot#656413/1477F).  Concomitant therapy included LIPITOR.  Subsequently the patient developed mild flu like symptoms.  Unspecified medical attention was sought.  Subsequently, after about 1 day the patient recovered.  No other information was provided.  There was no product quality complaint involved.  Additional information is not expected.
Age: 90.0
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a physician concerning a 90 year old male who on 27-JUL-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  On 30-JUL-2007 the patient developed shingles.  Unspecified medical attention was sought and the patient was put on VALTREX.  At the time of the report, the patient had not recovered.  A product quality complaint was not involved.  Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Headache
Clinical narrative: Information has been received from a pharmacist concerning a male patient in his 60's with hypothyroidism who on 17-JUL-2007 was vaccinated with Zostavax (Oka/Merck).  Concomitant therapy included levothyroxine Na and testosterone.  On approximately 29-JUL-2007, the patient experienced headaches.  The patient's headaches persisted.  Additional information has been requested.
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster, Incorrect route of drug administration
Clinical narrative: Information has been received from a physician concerning a male who was vaccinated IM with a dose of Zostavax (Oka/Merck).  The patient presented to the office a couple of days after receiving the Zostavax with a rash and the physician diagnosed him with shingles.  At the time of the report the patient's outcome was not reported.
Sex: F
Vaccine: VARZOS
Symptoms: Induration
Clinical narrative: Information has been received from a physician concerning a female in her 60's who was vaccinated with Zostavax (Oka/Merck) for the treatment of shingles.  Subsequently the patient experienced induration.  Subsequently, the patient recovered from induration.  Additional information has been requested.
Sex: U
Vaccine: VARZOS
Symptoms: Erythema, Induration, Rash
Clinical narrative: Information has been received from a physician concerning a patient who was vaccinated on an unspecified date with a dose of Zostavax (Oka/Merck).  Subsequently, on an unspecified date the patient experienced a "rash-like reaction with redness and hardness." It is unspecified if medical attention was sought.  The outcome is not reported.  This is one of several reports from the same reporter.  Additional information has been requested.
Age: 67.0
Sex: F
Vaccine: VARZOS
Symptoms: Blister, Burning sensation, Pruritus, Rash vesicular, Scab
Clinical narrative: Information has been received from a physician concerning a 67 year old female with a penicillin allergy, allergic reaction to tetracycline and an allergic reaction to barbiturates who on 18-JUN-2007 (also reported as 31-MAY-2007) was vaccinated with a dose of Zostavax (Oka/Merck).  Concomitant therapy included SUDAFED, BENADRYL, cyclobenzaprine HCl (MSD), PROTONIX, folic acid, LIPITOR, aspirin, PLAVIX and corticosteroids vaginal cream (unspecified).  On 19-JUN-2007 the patient was seen by the physician who identified varicella-like rashes on both sides of the patient's face and neck with some watery blisters.  Each lesion was about 2 mm.  The patient reported the rashes as being itchy and burning.  At the time of the consultation some of the rashes had crusted.  No lab studies were performed.  At the time of this report the patient's status was unknown.  There was no further information provided.  There was no product quality complaint involved.  Additional information has been requested. 12/21/07 This is in follow-up to report(s) previously submitted on 9/24/2007. Initial and follow up information has been received from a physician and a health care worker, concerning a 67 year old female with a penicillin allergy, allergic reaction to tetracycline and an allergic reaction to barbiturates, a history of coronary artery disease, hypercholesterolemia, restless leg syndrome, dyspepsia, and iron deficiency who on 31-MAY-2007 (previously reported as 18-JUN-2007) was vaccinated with a dose of ZOSTAVAX (Oka/Merck). Concomitant therapy included SUDAFED, BENADRYL, cyclobenzaprine HCl (MSD), PROTONIX, folic acid, LIPITOR, aspirin, PLAVIX and corticosteroids vaginal cream (unspecified). On 01-JUN-2007 (previously reported as 19-JUN-2007) the patient was seen by the physician who identified varicella-like rashes on both sides of the patient's face and neck with some watery blisters. Each lesion was about 2 mm. The patient reported the rashes as being itchy and burning. At the time of the consultation some of the rashes had crusted. No lab studies were performed. At the time of this report the patient's status was unknown. In follow up information it was noted that within 24 hours of vaccination the patient's skin "felt weird". The patient's varicella like rash lasted 2 weeks and eventually spread to her neck, fingers and left hand. The patient had another breakout with the same symptoms 2 months after the injection. There was no further information provided. There was no product quality complaint involved. Additional information has been requested.
Age: 68.0
Sex: F
Vaccine: VARZOS
Symptoms: Erythema, Mass, Pain, Skin warm
Clinical narrative: Information has been received from a 68 year old female medical receptionist (180 pounds, 62 inches) who on 20-JUL-2007 at 10:00 AM was vaccinated in her left upper arm with Zostavax (Oka/Merck) (lot # 656607/0163U).  She had no illness at the time of her vaccination.  On 21-JUL-2007 the patient developed a red bump, approximately 2 inches across which was warm and painful the first day.  It spread to 5 inches the second day, then it was 2 inches, still warm and a little painful when touched.  The patient considered the events to be non serious.  The patient's outcome was not reported.  Additional information is not expected.
Age: 60.0
Sex: F
Vaccine: VARZOS
Symptoms: Nuclear magnetic resonance imaging, Pain, X-ray
Clinical narrative: Information has been received from a patient's daughter concerning a 60 year old female with no pertinent medical history who in "February or March 2007", was vaccinated subcutaneously with a dose of Zostavax (Oka/Merck).  Concomitant therapy included LEXAPRO.  On 24-JUL-2007 the patient developed severe pain under her right shoulder that she describes as similar to "post herpetic neuralgia".  The patient never developed any type of rash.  Unspecified medical attention was sought.  X-rays and MRI studies were performed.  At the time of this report the patient had not recovered.  There was no further information provided.  There was no product quality complaint involved.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Pruritus
Clinical narrative: Information has been received from a physician concerning a female patient who on an unspecified date was vaccinated subcutaneously with a first dose of Zostavax (Oka/Merck). Subsequently, the patient experienced "itching about half an hour after receiving the vaccine".  Unspecified medical attention was sought.  The patient recovered on the same day of vaccination.  No product quality complaint was involved.  Additional information has been requested.
Age: 83.0
Sex: F
Vaccine: VARZOS
Symptoms: Herpes zoster, Pain, Rash
Clinical narrative: Information has been received from a physician concerning an 83 year old female who on 30-MAY-2007 was vaccinated with a "single dose" of Zostavax (Oka/Merck) injection.  On that same day the patient received a cyanocobalamin injection.  On 06-JUN-2007 after the patient received a dose of Zostavax (Oka/Merck), the patient experienced pain and a rash in her buttocks and vaginal area.  The rash was determined to be a full blown case of shingles.  The patient was prescribed acyclovir and MEDROL, a steroid.  The patient was seen again on 15-JUN-2007 and was determined to have had possibly postherpetic neuralgia.  As of 24-JUL-2007 the patient continued to recover.  Additional information has been requested.
Age: 68.0
Sex: M
Vaccine: VARZOS
Symptoms: Urticaria
Clinical narrative: Information has been received from a medical assistant concerning a 68-year-old male who was vaccinated with a dose of Zostavax (Oka/Merck).  On an unspecified date the patient developed a welt.  It is unknown if medical attention was sought.  The outcome is not reported.  This is one of several patients from the same source.  Additional information has been requested.
Age: 65.0
Sex: F
Vaccine: VARZOS
Symptoms: Chest discomfort, Cough
Clinical narrative: Information has been received from a 65 year old female who on approximately 24-JUN-2007 was vaccinated with Zostavax (Oka/Merck).  There was no concomitant medication.  On approximately 24-JUN-2007, the patient experienced a non-stop cough and tickling feeling in chest while coughing.  The patient's non-stop cough and tickling feeling in chest while coughing persisted.  Additional information has been requested. 12/21/07 This is in follow-up to report(s) previously submitted on 9/24/2007. In follow-up, it was reported that the patient's last office visit was 21-JUN-2007. The patient did not mention any adverse experiences pertaining to ZOSTAVAX. At the time of reporting, the patient was seeing another physician. Additional information is not expected.
Age: 62.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site erythema, Injection site warmth
Clinical narrative: Information has been received from a physician concerning a 61 year old female who on 10-JUL-2007 at 15:00 was vaccinated SC with a 0.65 ml dose of Zostavax (Oka/Merck)(lot # "3039U").  On 12-JUL-2007 at 15:00 the patient experienced redness and warmth around the injection site.  Unspecified medical attention was sought.  There was no product quality complaint involved.  Additional information from the administering health care professional indicated that the patient was going to watch the affected are. The patient's outcome was not reported. No further information was provided. Additional information has been requested.
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Blood pressure, Body temperature decreased, Burning sensation, Heart rate normal, Herpes zoster
Clinical narrative: Information has been received from a physician concerning an 84 year old female who on 13-JUL-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  On 17-JUL-2007 the patient developed a rash on the left T4 dermatome, diagnosed as shingles.  The patient was treated with ZOVIRAX lotion through a walk in clinic.  The patient was seen in her physician's office on 24-JUL-2007 with itching and burning.  The treatment continued.  The patient's shingles persisted.  There was no product quality complaint.  Information has been received from a certified medical assistant concerning the 84 year old female with cholesterol high, osteoporosis, hypertension, spinal stenosis nos, coronary artery disease, macular degeneration, bladder spasm and drug hypersensitivity ("TYLOX"), deep vein thrombosis, tinnitus, osteoarthritis, aortic stenosis, unilateral carpal tunnel syndrome and oedema peripheral who on 13-JUL-2007 was vaccinated with Zostavax (Oka/Merck).  Concomitant therapy included alendronate sodium (MSD), ATACAND, CELEBREX, INDERAL, aspirin, LASIX (furosemide), VESICARE, ezetimibe (MSD), CRESTOR, chondroitin sulfate sodium (+) glucosamine sulfate, "MSM", Vitamin B-12, Coenzyme Q10, fish oil, OCUVITE.  The medical assistant reported the patient received Zostavax (Oka/Merck) on 13-JUL-2007 at a health clinic and that 4 days after vaccination, the patient broke out in a rash on the left side that was determined to be a mild case of shingles.  Follow up information from the physician from 24-JUL-2007 of body temperature of 96.4 degrees F, pulse of 68 and blood pressure of 170/94.  The patient's rash appeared to be in the T8 dermatome on the left.  It was grouped vesicular lesions consistent with shingles.  The physician told the patient it was a wild type strain that cause the rash itself.  She was treated with acyclovir 800mg five times a day for one week.  As of 02-AUG-2007 the patient had recovered.  Additional information is not expected.
Age: 84.0
Sex: F
Vaccine: VARZOS
Symptoms: Pruritus, Rash
Clinical narrative: Information has been received from a physician concerning an 84 year old female who on 13-JUL-2007 was vaccinated with a dose of Zostavax (Oka/Merck).  On 17-JUL-2007 the patient developed a rash on the left T4 dermatome, diagnosed as shingles.  The patient was treated with ZOVIRAX lotion through a walk in clinic.  The patient was seen in her physician's office on 24-JUL-2007 with itching and burning.  The treatment continued.  The patient's shingles persisted.  There was no product quality complaint.  Information has been received from a certified medical assistant concerning the 84 year old female with cholesterol high, osteoporosis, hypertension, spinal stenosis nos, coronary artery disease, macular degeneration, bladder spasm and drug hypersensitivity ("TYLOX"), deep vein thrombosis, tinnitus, osteoarthritis, aortic stenosis, unilateral carpal tunnel syndrome and oedema peripheral who on 13-JUL-2007 was vaccinated with Zostavax (Oka/Merck).  Concomitant therapy included alendronate sodium (MSD), ATACAND, CELEBREX, INDERAL, aspirin, LASIX (furosemide), VESICARE, ezetimibe (MSD), CRESTOR, chondroitin sulfate sodium (+) glucosamine sulfate, "MSM", Vitamin B-12, Coenzyme Q10, fish oil, OCUVITE.  The medical assistant reported the patient received Zostavax (Oka/Merck) on 13-JUL-2007 at a health clinic and that 4 days after vaccination, the patient broke out in a rash on the left side that was determined to be a mild case of shingles.  Follow up information from the physician from 24-JUL-2007 of body temperature of 96.4 degrees F, pulse of 68 and blood pressure of 170/94.  The patient's rash appeared to be in the T8 dermatome on the left.  It was grouped vesicular lesions consistent with shingles.  The physician told the patient it was a wild type strain that cause the rash itself.  She was treated with acyclovir 800mg five times a day for one week.  As of 02-AUG-2007 the patient had recovered.  Additional information is not expected.
Age: 66.0
Sex: M
Vaccine: VARZOS
Symptoms: Blister, Rash erythematous, Rash vesicular
Clinical narrative: Information has been received from a 66 year old male consumer with no known allergies who on 29-MAY-2007 was vaccinated with a .65 ml dose of Zostavax (Oka/Merck) subcutaneously.  Concomitant therapy included NORVASC, HYTRIN, NAPROSYN and finasteride.  The consumer stated that "every week or so, a pox pops up".  He described them as "angry red circles with a white blister head in the center".  He had them on his ankle, upper arm and his legs.  He reported that they "don't hurt or itch" and they "go away eventually" but new ones appear.  Onset date was reported as "maybe 2 weeks after the shot" and outcome was reported as recovering.  The patient did not seek medical attention.  There was no product quality complaint.  Additional information has been requested.
Age: 72.0
Sex: F
Vaccine: VARZOS
Symptoms: Back pain, Chest pain, Herpes zoster, Rash
Clinical narrative: Information has been received from a vaccine coordinator concerning a 73 year old female who on an unspecified date in February 2007, was vaccinated with a single first dose of Zostavax (Oka/Merck).  On 12-JUL-2007 the patient developed "pain in her back and chest".  On 14-JUL-2007 the patient developed a "rash".  Unspecified medical attention was sought at a different facility from where the vaccine was administered.  At the time of this report the patient was recovering.  No further information was provided.  There was no product quality complaint involved.  Additional information has been requested. 12/21/07 This is in follow-up to report(s) previously submitted on 9/24/2007. Follow-up information was received concerning a 72-year-old (previously reported as 73) with allergies to sulfa, amoxicillin, LEVAQUIN, "robasise" and "biaxcin", who developed a case of shingles in June of 2007. She was treated with FAMVIR. On an unspecified date, the patient recovered. Additional information is not expected.
Age: 89.0
Sex: F
Vaccine: VARZOS
Symptoms: Burning sensation, Erythema, Herpes zoster, Incorrect route of drug administration, Pain
Clinical narrative: Information has been received from a physician concerning an 89 year old female with hypothyroidism, hypertension, atrial fibrillation and hyperlipidaemia and a history of herpes zoster (1999) who on 18-JUN-2007 was vaccinated with Zostavax (Oka/Merck) IM (lot no. 657764/0584U).  Concomitant therapy included SYNTHROID, ALTACE and COUMADIN.  On 19-JUN-2007 the patient noted pain and burning of the right side of her abdomen.  It was confirmed to be herpes zoster by the hives in the erythemic base along the nerve route.  She was treated with FAMVIR and LYRICA.  The patient's herpes zoster persisted with ongoing pain.  No further information is available.
Age: 89.0
Sex: F
Vaccine: VARZOS
Symptoms: Urticaria
Clinical narrative: Information has been received from a physician concerning an 89 year old female with hypothyroidism, hypertension, atrial fibrillation and hyperlipidaemia and a history of herpes zoster (1999) who on 18-JUN-2007 was vaccinated with Zostavax (Oka/Merck) IM (lot no. 657764/0584U).  Concomitant therapy included SYNTHROID, ALTACE and COUMADIN.  On 19-JUN-2007 the patient noted pain and burning of the right side of her abdomen.  It was confirmed to be herpes zoster by the hives in the erythemic base along the nerve route.  She was treated with FAMVIR and LYRICA.  The patient's herpes zoster persisted with ongoing pain.  No further information is available.
Age: 64.0
Sex: F
Vaccine: VARZOS
Symptoms: Skin lesion
Clinical narrative: Information has been received from a physician concerning a 64 year old female on 09-JUL-2007 was vaccinated with Zostavax (Oka/Merck).  On 23-JUL-2007, the patient was admitted to the emergency room with lesions on the patient's right ankle.  A possible herpes zoster outbreak was suspected, although they were unsure what the lesions really were.  In follow-up, it was reported that there was "nothing to get a specimen from" since the area had resolved.  Additional information has been requested.
Sex: F
Vaccine: VARZOS
Symptoms: Injection site pain, Injection site pruritus, Injection site swelling
Clinical narrative: Information has been received from a consumer concerning his wife who on 23-JUL-2007 was vaccinated with a single dose of Zostavax (Oka/Merck).  Subsequently, the patient developed an injection site reaction, including itching, swelling and pain at the injection site.  No further information was provided.  There was no product quality complaint involved.  Additional information is not expected.